Lipigon Pharmaceuticals Ab Stock Cash And Equivalents
| LPGO Stock | SEK 0.14 0.01 7.69% |
Lipigon Pharmaceuticals AB fundamentals help investors to digest information that contributes to Lipigon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Lipigon Stock. The fundamental analysis module provides a way to measure Lipigon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lipigon Pharmaceuticals stock.
Lipigon |
Lipigon Pharmaceuticals AB Company Cash And Equivalents Analysis
Lipigon Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Lipigon Pharmaceuticals Cash And Equivalents | 58.95 M |
Most of Lipigon Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lipigon Pharmaceuticals AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Lipigon Pharmaceuticals AB has 58.95 M in Cash And Equivalents. This is 92.82% lower than that of the Healthcare sector and 86.82% lower than that of the Biotechnology industry. The cash and equivalents for all Sweden stocks is 97.82% higher than that of the company.
Lipigon Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lipigon Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lipigon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lipigon Pharmaceuticals by comparing valuation metrics of similar companies.Lipigon Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
Lipigon Fundamentals
| Return On Equity | -1.7 | |||
| Return On Asset | -0.94 | |||
| Operating Margin | (338.33) % | |||
| Current Valuation | 5.58 M | |||
| Shares Outstanding | 20.24 M | |||
| Shares Owned By Insiders | 38.47 % | |||
| Shares Owned By Institutions | 12.51 % | |||
| Price To Book | 1.62 X | |||
| Price To Sales | 147.83 X | |||
| Revenue | 3.18 M | |||
| Gross Profit | (36.04 M) | |||
| EBITDA | (41.09 M) | |||
| Net Income | (41.11 M) | |||
| Cash And Equivalents | 58.95 M | |||
| Cash Per Share | 6.06 X | |||
| Current Ratio | 23.62 X | |||
| Book Value Per Share | 0.65 X | |||
| Cash Flow From Operations | (35.3 M) | |||
| Earnings Per Share | (4.65) X | |||
| Target Price | 5.4 | |||
| Market Capitalization | 25.81 M | |||
| Total Asset | 29.43 M | |||
| Z Score | -3.3 | |||
| Net Asset | 29.43 M |
About Lipigon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lipigon Pharmaceuticals AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lipigon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lipigon Pharmaceuticals AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lipigon Stock Analysis
When running Lipigon Pharmaceuticals' price analysis, check to measure Lipigon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipigon Pharmaceuticals is operating at the current time. Most of Lipigon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lipigon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipigon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lipigon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.